<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00734565</url>
  </required_header>
  <id_info>
    <org_study_id>M37P1</org_study_id>
    <nct_id>NCT00734565</nct_id>
  </id_info>
  <brief_title>Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b</brief_title>
  <official_title>A Phase I, Single-arm, Single-center Study to Investigate Safety and Reactogenicity of Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b in Healthy Children Aged 16 - 20 Months and Infants Aged 2 - 4 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will investigate safety and reactogenicity of a monovalent conjugated vaccine&#xD;
      against Haemophilus influenzae type b in healthy children&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of local and systemic reactions, adverse events (AEs), and serious adverse events (SAEs) after first vaccination dose will be evaluated.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of local and systemic reactions, adverse events (AEs), and serious adverse events (SAEs) after second vaccination dose will be evaluated.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Haemophilus Influenzae Type b</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Haemophilus influenzae type b</intervention_name>
    <description>1 dose monovalent conjugated vaccine against Haemophilus influenzae type b in children aged 16 - 20 months and infants aged 2 - 4 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants of either sex, aged 16 - 20 months / 2 - 4 months&#xD;
&#xD;
          -  in good health as determined by: medical history physical examination clinical&#xD;
             judgment of the investigator;&#xD;
&#xD;
          -  available for all visits scheduled in the study and able to comply with all study&#xD;
             regulations;&#xD;
&#xD;
          -  written informed consent obtained, from at least one parent or legal guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  parent or legal guardian is unwilling or unable to give written informed consent to&#xD;
             participate in study;&#xD;
&#xD;
          -  infants who presented a previous disease potentially related to Haemophilus influenzae&#xD;
             type b;&#xD;
&#xD;
          -  infants who had household contact and/or intimate exposure in the previous 30 days to&#xD;
             an individual with ascertained Haemophilus influenzae type b disease;&#xD;
&#xD;
          -  infants who have received any other Haemophilus influenzae type b immunization dose&#xD;
             before (for 16-20 months old children who have received a booster vaccination&#xD;
             already);&#xD;
&#xD;
          -  premature (before 37th week of gestation) or birth weight less than 2500 g;&#xD;
&#xD;
          -  history of anaphylactic shock, asthma, urticaria or other allergic reaction after&#xD;
             previous vaccinations or hypersensitivity to any vaccine component;&#xD;
&#xD;
          -  fever ≥38.0 °C (axillary body temperature) and/or significant acute or chronic&#xD;
             infection requiring systemic antibiotic or antiviral therapy within the past 7 days&#xD;
             before enrollment;&#xD;
&#xD;
          -  subjects with any serious chronic disease such as cardiac, neurological, metabolic,&#xD;
             hematologic, or neoplastic disease;&#xD;
&#xD;
          -  known/suspected immunodeficiency, or autoimmune disease, or any immunologic disorder;&#xD;
&#xD;
          -  subjects with any neurological disorder, e.g., epilepsy or history of seizure&#xD;
             disorder;&#xD;
&#xD;
          -  subjects with a clinically significant genetic anomaly;&#xD;
&#xD;
          -  treatment with corticosteroids or other immunosuppressive drugs;&#xD;
&#xD;
          -  treatment with parenteral immunoglobulin preparation, blood products, and/or plasma&#xD;
             derivatives (or: within the past 3 months - applicable for children 16 - 20 months);&#xD;
&#xD;
          -  any vaccination administered within 2 weeks (14 days) before enrollment;&#xD;
&#xD;
          -  participation in any other investigational trial simultaneously;&#xD;
&#xD;
          -  planned surgery during the study period;&#xD;
&#xD;
          -  any condition, which, in the opinion of the investigator, might interfere with the&#xD;
             evaluation of the study objective&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>20 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vaccination site</name>
      <address>
        <city>Shijiazhuang</city>
        <zip>050800</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>August 12, 2008</study_first_submitted>
  <study_first_submitted_qc>August 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <last_update_submitted>February 6, 2012</last_update_submitted>
  <last_update_submitted_qc>February 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>prevention</keyword>
  <keyword>haemophilus influenzae type b</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Haemophilus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

